Lenz Robert A. 4
4 · Neumora Therapeutics, Inc. · Filed Sep 16, 2024
Insider Transaction Report
Form 4
Lenz Robert A.
Head of R&D
Transactions
- Sale
Common Stock
2024-09-12$11.43/sh−32,948$376,665→ 369,993 total
Footnotes (2)
- [F1]Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 12, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
- [F2]This transaction was executed in multiple trades in prices ranging from $11.22 to $11.6050, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.